TY - JOUR
T1 - Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex
AU - Okamoto, Naoki
AU - Mizote, Keisuke
AU - Honda, Hiroe
AU - Saeki, Akinori
AU - Watanabe, Yasuharu
AU - Yamaguchi-Miyamoto, Tomomi
AU - Fukui, Ryutaro
AU - Tanimura, Natsuko
AU - Motoi, Yuji
AU - Akashi-Takamura, Sachiko
AU - Kato, Tatsuhisa
AU - Fujishita, Shigeto
AU - Kimura, Takahito
AU - Ohto, B. Umeharu
AU - Shimizu, Toshiyuki
AU - Hirokawa, Takatsugu
AU - Miyake, Kensuke
AU - Fukase, Koichi
AU - Fujimoto, Yukari
AU - Nagai, Yoshinori
AU - Takatsu, Kiyoshi
N1 - Funding Information:
This work was supported by Hokuriku Life Science Cluster, MEXT Regional Innovation Strategy Support Program (to K. T.); Hokuriku Innovation Clus-ter for Health Science, MEXT Regional Innovation Cluster Program, Toyama/Ishikawa Region (to K. T.); Grants-in-aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) JSPS KAKENHI JP16K19596 (to N. O.), JP16K19532 (to Y. W.), and JP15K07960 (to H. H.); NEXT Program (LR025 to Y. F.); and JST, PRESTO (JPMJPR13M1 to Y.N.). This work supported in part by the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Infor-matics, and Structural Life Science) from the Japan Agency for Medical Research and Development (to T. H.). Our laboratory (Dept. of Immunobi-ology and Pharmacological Genetics, University of Toyama) has Grant/Re-search support from Teika Pharmaceutical Co., Ltd. N. O., T. Kato, S. F., and T. Kimura are employees of Teika Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2017/9/15
Y1 - 2017/9/15
N2 - The Toll-like receptor 4 (TLR4)/myeloid differentiation factor- 2 (MD-2) complex is essential for LPS recognition and induces innate immune responses against Gram-negative bacteria. As activation of TLR4/MD-2 is also critical for the induction of adaptive immune responses, TLR4/MD-2 agonists have been developed as vaccine adjuvants, but their efficacy has not yet been ascertained. Here, we demonstrate that a funiculosin (FNC) variant, FNC-RED, and FNC-RED and FNC derivatives are agonists for both murine and human TLR4/MD-2. FNCRED induced nuclear factor-B (NF-B) activation via murine TLR4/MD-2, whereas FNC had no TLR4/MD-2 stimulatory activity. Biacore analysis revealed that FNC-RED binds to murine TLR4/MD-2 but not murine radioprotective 105 (RP105)/myeloid differentiation factor-1 (MD-1), another LPS sensor. FNC-RED induced CD14-independent expressions of pro-inflammatory cytokines and co-stimulatory molecules in murine macrophages and dendritic cells. In contrast, FNC-RED stimulation was reduced in CD14-dependent LPS responses, including dimerization and internalization of TLR4/MD-2 and IFN-κ expression. FNC-RED-induced IL-12p40 production from murine dendritic cells was dependent on NF-κ B but not MAPK pathway. In addition, fetal bovine serum augmented lipid A-induced NF-κ B activation but blocked FNC-RED-mediated responses. Two synthetic phosphate group-containing FNC-RED and FNC derivatives, FNC-RED-P01 and FNC-P01, respectively, activated human TLR4/MD-2, unlike FNC-RED. Finally, computational analysis revealed that this species-specific activation by FNC-REDandFNC-RED-P01resulted from differences in electrostatic surface potentials between murine and human TLR4/MD-2. We conclude that FNC-RED and its synthetic derivative represent a novel category of murine and human TLR4/MD-2 agonist.
AB - The Toll-like receptor 4 (TLR4)/myeloid differentiation factor- 2 (MD-2) complex is essential for LPS recognition and induces innate immune responses against Gram-negative bacteria. As activation of TLR4/MD-2 is also critical for the induction of adaptive immune responses, TLR4/MD-2 agonists have been developed as vaccine adjuvants, but their efficacy has not yet been ascertained. Here, we demonstrate that a funiculosin (FNC) variant, FNC-RED, and FNC-RED and FNC derivatives are agonists for both murine and human TLR4/MD-2. FNCRED induced nuclear factor-B (NF-B) activation via murine TLR4/MD-2, whereas FNC had no TLR4/MD-2 stimulatory activity. Biacore analysis revealed that FNC-RED binds to murine TLR4/MD-2 but not murine radioprotective 105 (RP105)/myeloid differentiation factor-1 (MD-1), another LPS sensor. FNC-RED induced CD14-independent expressions of pro-inflammatory cytokines and co-stimulatory molecules in murine macrophages and dendritic cells. In contrast, FNC-RED stimulation was reduced in CD14-dependent LPS responses, including dimerization and internalization of TLR4/MD-2 and IFN-κ expression. FNC-RED-induced IL-12p40 production from murine dendritic cells was dependent on NF-κ B but not MAPK pathway. In addition, fetal bovine serum augmented lipid A-induced NF-κ B activation but blocked FNC-RED-mediated responses. Two synthetic phosphate group-containing FNC-RED and FNC derivatives, FNC-RED-P01 and FNC-P01, respectively, activated human TLR4/MD-2, unlike FNC-RED. Finally, computational analysis revealed that this species-specific activation by FNC-REDandFNC-RED-P01resulted from differences in electrostatic surface potentials between murine and human TLR4/MD-2. We conclude that FNC-RED and its synthetic derivative represent a novel category of murine and human TLR4/MD-2 agonist.
UR - http://www.scopus.com/inward/record.url?scp=85029573303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029573303&partnerID=8YFLogxK
U2 - 10.1074/jbc.M117.791780
DO - 10.1074/jbc.M117.791780
M3 - Article
C2 - 28754693
AN - SCOPUS:85029573303
SN - 0021-9258
VL - 292
SP - 15378
EP - 15394
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 37
ER -